300
Views
25
CrossRef citations to date
0
Altmetric
Psoriasis & other inflammatory diseases

Certolizumab pegol – A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease

, , , , &
Pages 67-69 | Received 26 Jan 2015, Accepted 20 Mar 2015, Published online: 24 Apr 2015

References

  • Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409
  • Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, Pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45:202–10
  • Thrash B, Patel M, Shah KR, et al. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68:211.e1–33; quiz 244–6
  • Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg. 1991;78:676–78
  • Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646–54
  • Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for Pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273–83
  • Brooklyn TN, Dunill MG, Shetty A, et al. Infliximab for the treatment of Pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut. 2006;55:505–9
  • Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821–6
  • Reguiaï Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol. 2007;8:67–77
  • Zold E, Nagy A, Devenyi K, et al. Successful use of adalimumab for treating fistulizing Crohn’s disease with Pyoderma gangrenosum: two birds with one stone. World J Gastroenterol. 2009;15:2293–5
  • Cinotti E, Labeille B, Perrot JL, et al. Certolizumab for the treatment of refractory disseminated Pyoderma gangrenosum associated with rheumatoid arthritis. Clin Exp Dermatol. 2014;39:750–1

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.